Latest news and press releases about Prelude Therapeutics Incorporated (PRLD): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme.
Price
| Price | $4.47 |
| Market Cap | $254M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.24 |
| EV / EBITDA | -5.13 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -75.35% |
| Return on Invested Capital | -43.74% |
| Return on Assets | -31.94% |
| Gross Margin | 98.26% |
| Operating Margin | -300.56% |
| Net Margin | -269.75% |
Related companies: AVTX · CRBU · ENTA · EPRX · FHTX · IMRX · IVA
Explore sector: Healthcare · Biotechnology
More sections of PRLD: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks